Question explored with the scientific record
Ivermectin for Covid. What is the dosage?
There is no proven dose of ivermectin for COVID, because the best trials found no benefit to dose.
The honest answer to "what dose" is that the question assumes a benefit that the strongest evidence does not show. A 2026 meta-analysis of 40 randomized trials and 23,243 people found no significant effect of ivermectin on infection, death, or adverse events, across doses from 0.2 to 1.2 mg/kg [6]. The largest trials tested real doses and came up empty: 300 mcg/kg daily for five days did not shorten symptom resolution [5], and 0.4 mg/kg daily for five days did not prevent progression to severe disease [2]. The one pharmacokinetic study that modeled dosing concluded the approved oral dose cannot reach lung concentrations that inhibit the virus, and even daily high-dose simulations reached only a fraction of the needed level [1].
The trials that did report benefit were weaker by design. A Baghdad trial using 200 mcg/kg plus doxycycline found faster recovery, but its severe-case mortality difference was not statistically significant and its randomization was by odd/even dates [4]. An Abuja cohort using 200 mcg/kg daily found faster clearance and zero deaths, but it was not randomized and the arms came from different variant waves [3]. A Tucumán trial used 24 mg weekly and reported more discharges, yet its own protocol suggests patients self-selected into treatment [8]. Reviews that pooled these positive studies were later shown to rest partly on a withdrawn trial with copied data cells [7].
| Regimen tested | Setting | Result |
|---|---|---|
| 300 mcg/kg x 5 days | Mild, outpatient | No faster symptom resolution [5] |
| 0.4 mg/kg x 5 days | Mild-moderate, at risk | No less progression to severe [2] |
| 200 mcg/kg + doxycycline | Hospitalized | Faster recovery, mortality not significant [4] |
| 24 mg weekly x 4 | Mild, outpatient | More discharge, self-selection flaw [8] |
My call: there is no dose to recommend, because the well-run trials at every dose tested failed to show benefit, and the positive signals come from designs that cannot separate the drug from bias. Confidence: moderate.
Sources used 8
-
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19
A pharmacokinetic modeling study concludes that the approved oral dose of ivermectin is unlikely to reach inhibitory lung concentrations against SARS-CoV-2, suggesting limited efficacy at standard dosing and proposing exploration of higher dosing, alternative delivery (e.g., inh…
DOI: 10.1002/cpt.1889 -
Is Ivermectin Effective in Treating COVID-19?
A systematic review of 18 studies found ivermectin associated with lower mortality, shorter hospitalization, and faster RT-PCR negativity in some COVID-19 trials, but evidence was mixed and insufficient to recommend ivermectin as a therapeutic agent.
DOI: 10.3389/fphar.2022.858693 -
A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality
In a non-randomized Abuja cohort, ivermectin-based COVID-19 treatment was associated with faster viral clearance, shorter time to discharge, and lower mortality than non-ivermectin regimens after propensity matching.
DOI: 10.9734/jpri/2022/v34i44a36328 -
Controlled Randomized Clinical Trial on Using Ivermectin with Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq
In a randomized trial of 140 COVID-19 patients in Baghdad, adding ivermectin plus doxycycline to standard care shortened mean recovery time (10.61 vs 17.9 days) and reduced severe-case mortality (0/11 vs 6/22) and progression to critical disease (1/11 vs 7/22) compared with stan…
DOI: 10.22578/ijms.19.1.14 -
Ivermectin - an antiviral drug for the COVID-19 pandemic?
This narrative review concludes that ivermectin cannot be recommended for treating COVID-19 because robust trials showed no significant benefit in key clinical outcomes, although some lower-quality studies reported positive findings.
DOI: 10.12746/swrccc.v11i46.1141 -
The role of ivermectin in the prevention and treatment of SARS-CoV-2 infection: a meta-analysis of randomized controlled trials
In 40 RCTs (23,243 participants), ivermectin showed no statistically significant preventive or therapeutic benefit for SARS-CoV-2 infection, with no significant effects on infection rate, mortality, adverse events, or most secondary outcomes.
DOI: 10.1186/s12879-026-13195-9 -
Ivermectin and the Integrity of Healthcare Evidence During COVID-19
Ivermectin lacks reliable evidence of benefit for COVID-19; prominent supportive reviews rested on flawed, misclassified, or withdrawn studies that critical appraisal can expose.
DOI: 10.3389/fpubh.2022.788972 -
Randomized trials - Ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers
In a cluster-randomized trial of 254 outpatients with mild COVID-19 in Tucumán, Argentina, oral ivermectin plus symptomatic treatment was associated with significantly higher medical discharge at 28 days and greater symptom reduction from days 5–9 than symptomatic treatment alon…
DOI: 10.33448/rsd-v11i8.30844